2021 Interim Results Announcement-Investor Calendar-Hua Medicine

Our Science

Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

Portfolio Advisory Board

Senior Scientific Advisory Board

Investor Relations

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

2021 Interim Results Announcement

Hua Medicine

Aug 19, 2021

3272

9 August 2021(星期一)

2021 Interim Results Announcement

Dear Investors and Analysts,

9 August 2021 – Hua Medicine (2552.HK) ("Hua Medicine" or the "Company") cordially invites you or your representative to attend the online webinar in relation to its 2021 interim results on 19 August 2021 (Thursday) at 3:00 PM Hong Kong Time.

During the webinar, management will review the business and financial performance in the first half of 2021 and share with you their future plans.

Details of the webinar are as follows:


Date:	19 August 2021 (Thursday)
Time:	Login starts: 2:45PM Hong Kong Time Meeting starts: 3:00PM Hong Kong Time
Duration:	1 hour (including Q&A session)
Meeting Language:	English
Management:	Mr. Li Chen, Chief Executive Officer and Chief Scientific Officer Mr. George Lin, Chief Financial Officer and Executive Vice President
RSVP:	Registration Link: https://icaasia.zoom.us/webinar/register/WN_AV_p5Uu3TZqxaXoixeG4UQ (Please register via the link above by 19 August 2021) 1. Registration is open to invited participants only. All registration will be subject to management approval. 2. Upon successful registration, a personalized meeting link will be sent to the registered email. Please join the meeting via the link on the date of the meeting.
Q&A Arrangement:	If you would like to raise questions, please send your questions to huamedicine@icaasia.com from now till 19 August 2021 (Thursday). Management will address the received questions during the Q&A session after the presentation. Subject to the meeting time, you may also raise your questions during the Q&A session.
About Hua Medicine	Hua Medicine is a leading, innovative biotechnology company in China focused on developing novel therapies for diseases with unmet medical needs. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA stage, and it has successfully completed two Phase III registration trials in China for dorzagliatin. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.